Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neutral sphingomyelinase activation associated factor (NSMAF) is a WD-repeat scaffolding protein that couples the 55 kDa tumor necrosis factor receptor (TNFR1, p55 TNF-receptor) to neutral sphingomyelinase (N-SMASE). It acts by specifically binding to the N-SMASE activation domain of TNFR1, thereby facilitating TNF-mediated activation of neutral sphingomyelinase, which is involved in the generation of ceramide—a bioactive lipid mediator of inflammation, apoptosis, and stress responses. NSMAF is required for several tumor necrosis factor (TNF)-induced cellular responses, including apoptosis and inflammatory signaling. Diseases associated with NSMAF include some neurodegenerative disorders (e.g., Alzheimer’s disease) and rare immune/lysosomal diseases (e.g., Chediak-Higashi syndrome). Alternative splicing of the gene can produce multiple transcript variants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neutral sphingomyelinase activation associated factor (NSMAF).